{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:19:33Z","timestamp":1747210773681,"version":"3.40.5"},"reference-count":65,"publisher":"Universidad del Valle","issue":"2","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["colombiamedica.univalle.edu.co"],"crossmark-restriction":true},"short-container-title":["Colomb Med"],"abstract":"<jats:p>Drug repositioning is a strategy that identifies new uses of approved drugs, to treat\u00a0conditions different from their original purpose. With the advance of COVID-19 and the\u00a0declaration of a pandemic; It has become the closest alternative to slow the advance\u00a0of the virus. Antimalarial, antiviral drugs, antibiotics, glucocorticoids, monoclonal\u00a0antibodies, among others, are being studied; his findings, although preliminary, could\u00a0establish a starting point in the search for a solution.\r\nIn this article, we present a\u00a0selection of drugs, of different classes and with potential activity to combat COVID-19,\u00a0whose trials are ongoing; and as proofs of concept, double blind, event-driven add-on,\u00a0would allow proposing research that generates results in less time and preserving the\u00a0quality criteria for drug development and approval by regulatory agencies.<\/jats:p>","DOI":"10.25100\/cm.v51i2.4279","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T22:41:29Z","timestamp":1589928089000},"update-policy":"https:\/\/doi.org\/10.25100\/cm.crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Drug Repositioning for COVID-19"],"prefix":"10.25100","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9129-0183","authenticated-orcid":false,"given":"Vicente","family":"Benavides-Cordoba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10728","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"47076","unstructured":"WHO. Coronavirus Disease (COVID-19) - events as they happen 2020 [Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen."},{"key":"47078","doi-asserted-by":"crossref","unstructured":"Li G, De Clercq E. Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-50. https:\/\/doi.org\/10.1038\/d41573-020-00016-0","DOI":"10.1038\/d41573-020-00016-0"},{"key":"47080","unstructured":"Prompetchara E, Ketloy C, Palaga T. Immune Responses in COVID-19 and Potential Vaccines: Lessons Learned From SARS and MERS Epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9."},{"key":"47082","doi-asserted-by":"crossref","unstructured":"Della G, Jonsdottir, I. Lewis D. Challenges in Early Clinical Development of Adjuvanted Vaccines. Vaccine. 2015;33:47-51. https:\/\/doi.org\/10.1016\/j.vaccine.2015.02.031","DOI":"10.1016\/j.vaccine.2015.02.031"},{"key":"47084","doi-asserted-by":"crossref","unstructured":"Esch EW. BA, Huh D. Organs-on-chips at the Frontiers of Drug Discovery. Nature reviews Drug discovery. 2015;14(4):248-60. https:\/\/doi.org\/10.1038\/nrd4539","DOI":"10.1038\/nrd4539"},{"key":"47086","doi-asserted-by":"crossref","unstructured":"Lythgoe MP., Rhodes CJ., Ghataorhe P., Attard M., Wharton J., Wilkins MR. Why Drugs Fail in Clinical Trials in Pulmonary Arterial Hypertension, and Strategies to Succeed in the Future. Pharmacology & therapeutics. 2016;164:195-203. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.04.012","DOI":"10.1016\/j.pharmthera.2016.04.012"},{"key":"47088","doi-asserted-by":"crossref","unstructured":"Waring MJ., Arrowsmith J., Leach AR., Leeson PD., Mandrell S., Owen RM., et al. An Analysis of the Attrition of Drug Candidates From Four Major Pharmaceutical Companies. Nature reviews Drug discovery. 2015;14(7):475-88. https:\/\/doi.org\/10.1038\/nrd4609","DOI":"10.1038\/nrd4609"},{"key":"47090","doi-asserted-by":"crossref","unstructured":"Pushpakom S, Iorio F, Eyers P, Escott K, Hopper S, Wells A, et al. Drug Repurposing: Progress, Challenges and Recommendations. Nature reviews Drug discovery. 2019;18(1):41-58. https:\/\/doi.org\/10.1038\/nrd.2018.168","DOI":"10.1038\/nrd.2018.168"},{"key":"47092","doi-asserted-by":"crossref","unstructured":"Ashburn T, Thor K. Drug Repositioning: Identifying and Developing New Uses for Existing Drugs. Nature reviews Drug discovery. 2004;3(8):673-83. https:\/\/doi.org\/10.1038\/nrd1468","DOI":"10.1038\/nrd1468"},{"key":"47094","doi-asserted-by":"crossref","unstructured":"Minghetti P, Lanati E, Godfrey J, Sol\u00e0-Morales O, O. W, S. S. From Off-Label to Repurposed Drug in Non-Oncological Rare Diseases: Definition and State of the Art in Selected EU Countries. MAP. 2017;1. https:\/\/doi.org\/10.5301\/maapoc.0000016","DOI":"10.5301\/maapoc.0000016"},{"key":"47096","doi-asserted-by":"crossref","unstructured":"Breckenridge A, Jacob R. Overcoming the Legal and Regulatory Barriers to Drug Repurposing. Nature reviews Drug discovery. 2019;18(1). https:\/\/doi.org\/10.1038\/nrd.2018.92","DOI":"10.1038\/nrd.2018.92"},{"key":"47098","doi-asserted-by":"crossref","unstructured":"Nosengo N. Can You Teach Old Drugs New Tricks? Nature. 2016;534(7607):314-6. https:\/\/doi.org\/10.1038\/534314a","DOI":"10.1038\/534314a"},{"key":"47100","doi-asserted-by":"crossref","unstructured":"Corsello S, Bittker J, Liu Z, Gould J, McCarren P, Hirschman J, et al. The Drug Repurposing Hub: A Next-Generation Drug Library and Information Resource. Nat Med. 2017;23(4):405-8. https:\/\/doi.org\/10.1038\/nm.4306","DOI":"10.1038\/nm.4306"},{"key":"47102","doi-asserted-by":"crossref","unstructured":"Cha Y, Erez T, Reynolds I, Kumar D, Ross J, Koytiger G, et al. Drug Repurposing From the Perspective of Pharmaceutical Companies. British journal of pharmacology. 2018;175(2):168-80. https:\/\/doi.org\/10.1111\/bph.13798","DOI":"10.1111\/bph.13798"},{"key":"47104","doi-asserted-by":"crossref","unstructured":"Sleire L, F\u00f8rde HE, Netland IA, Leiss L, Skeie BS, P\u00d8. E. Drug Repurposing in Cancer. Pharmacological research. 2017;124. https:\/\/doi.org\/10.1016\/j.phrs.2017.07.013","DOI":"10.1016\/j.phrs.2017.07.013"},{"key":"47106","doi-asserted-by":"crossref","unstructured":"Chen PC, Liu X, Y. L. Drug Repurposing in Anticancer Reagent Development. Combinatorial chemistry & high throughput screening. 2017;20(5):395-402. https:\/\/doi.org\/10.2174\/1386207319666161226143424","DOI":"10.2174\/1386207319666161226143424"},{"key":"47108","doi-asserted-by":"crossref","unstructured":"Gilbert DC., Vale C., Haire R., Coyle C., Langley RE. Repurposing Vitamin D as an Anticancer Drug. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016;28(1):36-41. https:\/\/doi.org\/10.1016\/j.clon.2015.10.004","DOI":"10.1016\/j.clon.2015.10.004"},{"key":"47110","doi-asserted-by":"crossref","unstructured":"Athauda D., Foltynie T. Drug Repurposing in Parkinson's Disease. CNS drugs. 2018;32(8):747-61. https:\/\/doi.org\/10.1007\/s40263-018-0548-y","DOI":"10.1007\/s40263-018-0548-y"},{"key":"47112","doi-asserted-by":"crossref","unstructured":"Mercorelli B., Pal\u00f9 G., Loregian A. Drug Repurposing for Viral Infectious Diseases: How Far Are We? Trends in microbiology. 2018;26(10):865-76. https:\/\/doi.org\/10.1016\/j.tim.2018.04.004","DOI":"10.1016\/j.tim.2018.04.004"},{"key":"47114","doi-asserted-by":"crossref","unstructured":"Konreddy AK., Rani GU., Lee K., Choi Y. Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics. Current medicinal chemistry. 2019;26(28):5363-88. https:\/\/doi.org\/10.2174\/0929867325666180706101404","DOI":"10.2174\/0929867325666180706101404"},{"key":"47116","doi-asserted-by":"crossref","unstructured":"Kruse RL., Vanijcharoenkarn K. Drug Repurposing to Treat Asthma and Allergic Disorders: Progress and Prospects. Allergy. 2018;73(2):313-22. https:\/\/doi.org\/10.1111\/all.13305","DOI":"10.1111\/all.13305"},{"key":"47118","doi-asserted-by":"crossref","unstructured":"Sisignano M., Parnham MJ., Geisslinger G. Drug Repurposing for the Development of Novel Analgesics. Trends in pharmacological sciences. 2016;37(3):172-83. https:\/\/doi.org\/10.1016\/j.tips.2015.11.006","DOI":"10.1016\/j.tips.2015.11.006"},{"key":"47120","doi-asserted-by":"crossref","unstructured":"Panchapakesan U., Pollock C. Drug Repurposing in Kidney Disease. Kidney international. 2018;94(1):40-8. https:\/\/doi.org\/10.1016\/j.kint.2017.12.026","DOI":"10.1016\/j.kint.2017.12.026"},{"key":"47122","doi-asserted-by":"crossref","unstructured":"Walton GM., Stockley JA., Griffiths D., Sadhra CS., Purvis T., Sapey E. Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD? Journal of clinical medicine. 2016;5(10). https:\/\/doi.org\/10.3390\/jcm5100089","DOI":"10.3390\/jcm5100089"},{"key":"47124","doi-asserted-by":"crossref","unstructured":"George CH., Mitchell AN., Preece R., Bannister ML., Yousef Z. Pleiotropic Mechanisms of Action of Perhexiline in Heart Failure. Expert opinion on therapeutic patents. 2016;26(9):1049-59. https:\/\/doi.org\/10.1080\/13543776.2016.1211111","DOI":"10.1080\/13543776.2016.1211111"},{"key":"47126","doi-asserted-by":"crossref","unstructured":"Korkmaz-Ic\u00f6z S., Radovits T., Szab\u00f3 G. Targeting Phosphodiesterase 5 as a Therapeutic Option Against Myocardial Ischaemia\/Reperfusion Injury and for Treating Heart Failure. British journal of pharmacology. 2018;175(2):223-31. https:\/\/doi.org\/10.1111\/bph.13749","DOI":"10.1111\/bph.13749"},{"key":"47128","doi-asserted-by":"crossref","unstructured":"Fuster V, Chesebro J. Aspirin for Primary Prevention of Coronary Disease. European heart journal. 1995;16 Suppl E. https:\/\/doi.org\/10.1093\/eurheartj\/16.suppl_E.16","DOI":"10.1093\/eurheartj\/16.suppl_E.16"},{"key":"47130","doi-asserted-by":"crossref","unstructured":"Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006;2(4):411-22. https:\/\/doi.org\/10.2147\/vhrm.2006.2.4.411","DOI":"10.2147\/vhrm.2006.2.4.411"},{"key":"47132","doi-asserted-by":"crossref","unstructured":"Baker NC., Ekins S., Williams AJ., Tropsha A. A Bibliometric Review of Drug Repurposing. Drug discovery today. 2018;23(3):661-72. https:\/\/doi.org\/10.1016\/j.drudis.2018.01.018","DOI":"10.1016\/j.drudis.2018.01.018"},{"key":"47134","unstructured":"COVID 19 - List Results - ClinicalTrials.gov 2020 [Available from: https:\/\/clinicaltrials.gov\/ct2."},{"key":"47136","doi-asserted-by":"crossref","unstructured":"Schlitzer M. Malaria Chemotherapeutics Part I: History of Antimalarial Drug Development, Currently Used Therapeutics, and Drugs in Clinical Development. ChemMedChem. 2007;2(7). https:\/\/doi.org\/10.1002\/cmdc.200600240","DOI":"10.1002\/cmdc.200600240"},{"key":"47138","doi-asserted-by":"crossref","unstructured":"Activity of a New Antimalarial Agent, Chloroquine (SN 7618). J Am Med Assoc. 1946;130:1069. https:\/\/doi.org\/10.1001\/jama.1946.02870160015006","DOI":"10.1001\/jama.1946.02870160015006"},{"key":"47140","doi-asserted-by":"crossref","unstructured":"Keyaerts E, Vijgen L, Maes P, Neyts J, Van M. In Vitro Inhibition of Severe Acute Respiratory Syndrome Coronavirus by Chloroquine. Biochem Biophys Res Commun. 2004;323(1):264-8. https:\/\/doi.org\/10.1016\/j.bbrc.2004.08.085","DOI":"10.1016\/j.bbrc.2004.08.085"},{"key":"47142","doi-asserted-by":"crossref","unstructured":"Gao J, Tian Z, Yang X. Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies. Biosci Trends. 2020;14(1):72-3. https:\/\/doi.org\/10.5582\/bst.2020.01047","DOI":"10.5582\/bst.2020.01047"},{"key":"47144","doi-asserted-by":"crossref","unstructured":"Costedoat-Chalumeau N, Dunogu\u00e9 B, Morel N, Guern V, Guettrot-Imbert G. Hydroxychloroquine: A Multifaceted Treatment in Lupus. Presse Med. 2014;43(6 Pt 2). https:\/\/doi.org\/10.1016\/j.lpm.2014.03.007","DOI":"10.1016\/j.lpm.2014.03.007"},{"key":"47146","unstructured":"PubChem. Hydroxychloroquine Compound Summary 2020 [Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/."},{"key":"47148","doi-asserted-by":"crossref","unstructured":"G H. Hydroxychloroquine: An Update. Lupus. 2018;27(9):1402-3. https:\/\/doi.org\/10.1177\/0961203318787040","DOI":"10.1177\/0961203318787040"},{"key":"47150","doi-asserted-by":"crossref","unstructured":"Yazdany J, Kim A. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M20-1334","DOI":"10.7326\/M20-1334"},{"key":"47152","doi-asserted-by":"crossref","unstructured":"Zhou D, Dai S, Tong Q. COVID-19: A Recommendation to Examine the Effect of Hydroxychloroquine in Preventing Infection and Progression. J Antimicrob Chemother. 2020. https:\/\/doi.org\/10.1093\/jac\/dkaa114","DOI":"10.1093\/jac\/dkaa114"},{"key":"47154","unstructured":"Barbosa J, Kaitis D, Freedman R, Le K, Lin X. Clinical outcomes of hydroxychloroquine in hospitalized p... Bibliovid. 2020(bibliovid-a-302)."},{"key":"47156","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M, et al. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. Int J Antimicrob Agents. 2020:105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"47158","doi-asserted-by":"crossref","unstructured":"Cunningham AG, H. Koh, D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24:91. https:\/\/doi.org\/10.1186\/s13054-020-2818-6","DOI":"10.1186\/s13054-020-2818-6"},{"key":"47160","doi-asserted-by":"crossref","unstructured":"Lai C, Shih T, Ko W, Tang H, Hsueh P. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus disease-2019 (COVID-19): The Epidemic and the Challenges. Int J Antimicrob Agents. 2020;55(3):105924. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105924","DOI":"10.1016\/j.ijantimicag.2020.105924"},{"key":"47162","doi-asserted-by":"crossref","unstructured":"Liu Y, Li J, Feng Y. Critical Care Response to a Hospital Outbreak of the 2019-nCoV Infection in Shenzhen, China. Crit Care. 2020;24(1):56. https:\/\/doi.org\/10.1186\/s13054-020-2786-x","DOI":"10.1186\/s13054-020-2786-x"},{"key":"47164","doi-asserted-by":"crossref","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients With Severe Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2007016","DOI":"10.1056\/NEJMoa2007016"},{"key":"47166","doi-asserted-by":"crossref","unstructured":"Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, et al. Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants. J Virol. 2005;79(10):5900-6. https:\/\/doi.org\/10.1128\/JVI.79.10.5900-5906.2005","DOI":"10.1128\/JVI.79.10.5900-5906.2005"},{"key":"47168","doi-asserted-by":"crossref","unstructured":"Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JKC, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013;31(12):1553-9. https:\/\/doi.org\/10.1016\/j.vaccine.2013.01.025","DOI":"10.1016\/j.vaccine.2013.01.025"},{"key":"47170","doi-asserted-by":"crossref","unstructured":"Masters PS. The Molecular Biology of Coronaviruses. Adv Virus Res. 2006;66:193-292. https:\/\/doi.org\/10.1016\/S0065-3527(06)66005-3","DOI":"10.1016\/S0065-3527(06)66005-3"},{"key":"47172","unstructured":"Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on Monoclonal Antibody Therapy as Potential Therapeutic Intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10-8."},{"key":"47174","doi-asserted-by":"crossref","unstructured":"Zhou Y, Qin Y, Lu Y, Sun F, Yang S, Harypursat V, et al. Effectiveness of Glucocorticoid Therapy in Patients With Severe Novel Coronavirus Pneumonia: Protocol of a Randomized Controlled Trial. Chin Med J. 2020. https:\/\/doi.org\/10.1097\/CM9.0000000000000791","DOI":"10.1097\/CM9.0000000000000791"},{"key":"47176","unstructured":"Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, et al. Thalidomide Combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia. 2020:020395."},{"key":"47178","doi-asserted-by":"crossref","unstructured":"Deftereos S, Siasos G, Giannopoulos G, Vrachatis D, Angelidis C, Giotaki S, et al. The GReek Study in the Effects of Colchicine in COvid-19 Complications Prevention (GRECCO-19 Study): Rationale and Study Design. Hellenic J Cardiol. 2020. https:\/\/doi.org\/10.1016\/j.hjc.2020.03.002","DOI":"10.1016\/j.hjc.2020.03.002"},{"key":"47180","doi-asserted-by":"crossref","unstructured":"Kupferschmidt K, Cohen J. Race to Find COVID-19 Treatments Accelerates. Science. 2020;367(6485):1412-3. https:\/\/doi.org\/10.1126\/science.367.6485.1412","DOI":"10.1126\/science.367.6485.1412"},{"key":"47182","doi-asserted-by":"crossref","unstructured":"Rosa S, Santos W. Clinical trials on drug repositioning of COVID-19. Pan American Health Organization. 2020. https:\/\/doi.org\/10.26633\/RPSP.2020.40","DOI":"10.26633\/RPSP.2020.40"},{"key":"47184","doi-asserted-by":"crossref","unstructured":"Wilson M, Fleming K, Kut iM, Looi L, Lag oN, Ru K. Access to Pathology and Laboratory Medicine Services: A Crucial Gap. Lancet. 2018;391(10133):1927-38. https:\/\/doi.org\/10.1016\/S0140-6736(18)30458-6","DOI":"10.1016\/S0140-6736(18)30458-6"},{"key":"47186","unstructured":"COVID-19: what science advisers must do now [Nature Briefing]. Nature Publishing Group; 2020 [updated 2020-03-18. Available from: https:\/\/media.nature.com\/original\/magazine-assets\/d41586-020-00772-4\/d41586-020-00772-4.pdf."},{"key":"47188","unstructured":"Global Coalition to Accelerate COVID-19 Clinical Research in Resource-Limited Settings. Lancet. 2020."},{"key":"47190","unstructured":"Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of Covid-19 in certain hospitalized patients, (2020)."},{"key":"47192","unstructured":"Charles H., Evans J, Suzanne T. Statistical Approaches to Analysis of Small Clinical Trials [Text]: National Academies Press (US); 2001. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/."},{"key":"47194","unstructured":"Brody T. Clinical Trials - 2nd Edition: Elsevier; 2016. Available from: https:\/\/www.elsevier.com\/books\/clinical-trials\/brody\/978-0-12-804217-5."},{"key":"47196","doi-asserted-by":"crossref","unstructured":"Mills A., Durepos G., Wiebe E. Event-Driven Research. 2010. In: Encyclopedia of Case Study Research [Internet]. Available from: https:\/\/methods.sagepub.com\/reference\/encyc-of-case-study-research\/n133.xml. https:\/\/doi.org\/10.4135\/9781412957397","DOI":"10.4135\/9781412957397"},{"key":"47198","doi-asserted-by":"crossref","unstructured":"Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2 - Mesenchymal Stem Cells Improves the Outcome of Patients With COVID-19 Pneumonia. Aging Dis. 2020;11(2):216-28. https:\/\/doi.org\/10.14336\/AD.2020.0228","DOI":"10.14336\/AD.2020.0228"},{"key":"47200","unstructured":"Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease 2020 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04325893."},{"key":"47202","unstructured":"Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 2020 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315298."},{"key":"47204","unstructured":"Zimmer C. Scientists Identify 69 Drugs to Test Against the Coronavirus. New York Times. 2020 20200322."}],"container-title":["Colombia Medica"],"original-title":[],"link":[{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/4279\/4762","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/4279\/4763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/4279\/4738","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/4279\/4739","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/4279\/4762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T17:58:53Z","timestamp":1722967133000},"score":1,"resource":{"primary":{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/view\/4279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":65,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,5,7]]}},"URL":"https:\/\/doi.org\/10.25100\/cm.v51i2.4279","relation":{},"ISSN":["1657-9534","0120-8322"],"issn-type":[{"type":"electronic","value":"1657-9534"},{"type":"print","value":"0120-8322"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"Yes","name":"crosschecked","label":"CrossChecked"},{"value":"Yes","name":"peer_reviewed","label":"Peer Reviewed"}]}}